Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Unaudited) - USD ($)	Redeemable Noncontrolling Interest [Member]	Mezzanine Equity [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2022	$ 885,028	$ 885,028	$ 20,782	$ 94,395,662		$ (79,207,786)	$ (536,734)	$ 14,671,924
Beginning balance, shares at Dec. 31, 2022			2,078,271
Mezzanine equity balance, shares at Dec. 31, 2022	1,000
Stock-based compensation				532,835				532,835
Foreign exchange translation gain							1,968	1,968
Net loss						(4,677,527)		(4,677,527)
Preferred dividends attributable to redeemable non-controlling interest	12,329	12,329		(12,329)				(12,329)
Accretion of embedded derivative to redemption value	110,991	110,991		(110,991)				(110,991)
Balance at Mar. 31, 2023	$ 1,008,348	1,008,348	$ 20,782	94,805,177		(83,885,313)	(534,766)	10,405,880
Ending balance, shares at Mar. 31, 2023			2,078,271
Mezzanine equity balance, shares at Mar. 31, 2023	1,000
Balance at Dec. 31, 2022	$ 885,028	885,028	$ 20,782	94,395,662		(79,207,786)	(536,734)	14,671,924
Beginning balance, shares at Dec. 31, 2022			2,078,271
Mezzanine equity balance, shares at Dec. 31, 2022	1,000
Proceeds from the exercise of warrants and preferred investment options and issuance, shares			418,000
Balance at Dec. 31, 2023			$ 27,392	100,815,851	$ (1,817,640)	(96,499,518)	(569,749)	1,956,336
Ending balance, shares at Dec. 31, 2023			2,739,315
Stock-based compensation				351,488				351,488
Common stock sold under the Equity Distribution Agreement, net of offering costs of $583,713			$ 16,680	1,792,109				1,808,789
Common stock sold under the Equity Distribution Agreement, shares			1,668,000
Issuance of direct offering shares (see Note 7)			$ 2,287	320,166				322,453
Exercise of Inducement Warrants for common stock, shares			228,690
Exercise of Inducement Warrants for common stock			$ 19,540	2,657,440				2,676,980
Exercise of Inducement Warrants for common stock, shares			1,954,000
Proceeds from the subscription receivable related to the issuance of Inducement Warrants, net of offering costs of $12,821 (see Note 7)				(12,821)	280,500			267,679
Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance (see Note 7)			$ 7,040	(7,040)	1,537,140			1,537,140
Proceeds from the exercise of warrants and preferred investment options and issuance, shares			704,000
Foreign exchange translation gain							17,906	17,906
Net loss						(2,456,915)		(2,456,915)
Preferred dividends attributable to redeemable non-controlling interest
Accretion of embedded derivative to redemption value
Balance at Mar. 31, 2024			$ 72,939	$ 105,917,193		$ (98,956,433)	$ (551,843)	$ 6,481,856
Ending balance, shares at Mar. 31, 2024			7,294,005